Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells

British Journal of Haematology

Volumn 122, Issue 2, 2003, Pages 260-268

  Bogner, Christian ^a   Ringshausen, Ingo ^a   Schneller, Folker ^a   Fend, Falko ^b   Quintanilla Martinez, Leticia ^b   Häcker, Georg ^a   Goetze, Katharina ^a   Oostendorp, Robert ^a   Peschel, Christian ^a   Decker, Thomas ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Apoptosis; Cell cycle; Lactacystin; Mantle cell lymphoma; Proteasome

Indexed keywords

CASPASE 8; CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; DNA; LACTACYSTIN; PROTEASOME; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; THYMIDINE; TRITIUM;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CYTOGENETICS; HUMAN; HUMAN CELL; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ACETYLCYSTEINE; APOPTOSIS; B-LYMPHOCYTES; BLOTTING, WESTERN; CASPASE 3; CASPASE 9; CASPASES; CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE; HUMANS; IN SITU NICK-END LABELING; LYMPHOMA, MANTLE-CELL; PROTEASE INHIBITORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038148285     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04438.x     Document Type: Article

References (44)

1. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S. & Elliott, P.J. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research, 1999, 2615-2622.
2. Almond, J.B. & Cohen, G.M. (2002) The proteasome: a novel target for cancer therapy. Leukemia, 16, 433-443.
3. Almond, J.B., Snowden, R.T., Hunter, A., Dinsdale, D., Cain, K. & Cohen, G.M. (2001) Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. Leukemia, 15, 1388-1397.
4. An, W.G., Hwang, S.G., Trepel, J.B. & Blagosklonny, M.V. (2000) Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia, 14, 1276-1283.
5. Bargonetti, J. & Manfredi, J.J. (2002) Multiple roles of the tumor suppressor p53. Current Opinion in Oncology, 14, 86-91.
6. Bernard, M., Gressin, R., Drenou, B., Branger, B., Caulet-Maugendre, S., Tass, P., Brousse, N., Valensi, F., Milpied, N., Voilat, L., Sadoun, A., Ghandour, C., Hunault, M., Leloup, R., Mannone, L., Hermine, O. & Lamy, T. (2001) Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia, 15, 1785-1791.
7. Bosch, F., Jares, P., Campos, E., Lopez-Guilermo, A., Piris, M.A., Villamor, N., Tassies, D., Jaffe, E.S., Montserrat, E., Rozman, C. & Cardesa, A. (1994) Prad-1/Cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood, 84, 2726-2732.
8. Campo, E., Raffeld, M. & Jaffe, E.S. (1999) Mantle-cell lymphoma. Seminars in Hematology, 36, 115-127.
9. Castillo, R., Mascarenhas, J., Telford, W., Chadburn, A., Friedman, S.M. & Schattner, E.J. (2000) Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4. Leukemia, 14, 292-298.
10. Chiarle, R., Budel, L.M., Skolnik, J., Frizzera, G., Chilosi, M., Corato, A., Pizzolo, G., Magdison, J., Montagnoli, A., Pagano, M., Maes, B., De Wolf-Peeters, C. & Inghirami, G. (2000) Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood, 95, 619-626.
11. Drexler, H.C.A. (1997) Activation of the cell death program by inhibition of proteasome function. Proceedings of the National Academy of Sciences of the United States of America, 94, 855-860.
12. Fenteany, G. & Schreibers, S.L. (1998) Lactacystin, proteasome function and cell fate. Journal of Biological Chemistry, 273, 8545-8548.
13. Freedman, A., Neuberg, D., Gribben, J.G., Mauch, P., Soiffer, R.J., Fisher, D.C., Anderson, K.C., Andersen, N., Schlossman, R., Kroon, M., Ritz, J., Aster, J. & Nadler, L.M. (1998) High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long term remission. Journal of Clinical Oncology, 16, 13-18.
14. Greiner, T.C., Moynihan, M.J., Chan, W.C., Lytle, D.M., Pedersen, A., Anderson, J.R. & Weisenburger, D.D. (1996) P53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood, 87, 4302-4310.
15. Gronbaek, K., Nedergaard, T., Andresen, M.K., Straten, P.T., Guldberg, P., Moller, P., Zeuthen, J., Ebbe-Hansen, N., Hou-Jensen, K. & Ralfkiaer, E. (1998) Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, 16, 15, 53 and pRB. Leukemia, 12, 1266-1271.
16. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K.C., Cleary, M.L., Delsol, G., De Wolf-Peeters, C., Falini, B., Gatter, K.C., Crogan, T.M., Isaacson, P.G., Knowles, D.M., Mason, D.Y., Muller-Hermelink, H.K., Pileri, S.A., Piris, M.A., Ralfkiaer, E. & Warnke, R.A. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361-1392.
17. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) World Health Organization classification of neoplastic diseases of the hematopoletic and lymphoid tissues: report of the clinical advisory committee meeting. Journal of Clinical Oncology, 17, 3835-3849.
18. Herr, I. & Debatin, K.M. (2001) Cellular stress response and apoptosis in cancer therapy. Blood, 98, 2603-2614.
19. Hideshima, T., Richardson, P., Chauhan, D., Palombella, VJ., Elliott, P.J., Adams, J. & Anderson, K.C. (2000) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 3071-3076.
20. Hirama, T. & Koeffler, P. (1995) Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood, 86, 841-854.
21. Howard, O.M., Gribben, J.G., Neuberg, D.S., Grossbard, M., Poor, C., Janicek, M.J. & Shipp, M.A. (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma. Molecular complete responses are not predictive of progression-free survival. Journal of Clinical Oncology, 20, 1288-1294.
22. Hu, X., Bryington, M., Fisher, A.B., Liang, X., Zhang, X., Cui, D., Datta, I. & Zuckerman, K.S. (2002) Ubiquitin/proteasome-dependent degradation of D-type cyclins is linked to tumor necrosis factor-induced cell cycle arrest. Journal of Biological Chemistry, 277, 16528-16537.
23. Jadayel, D.M., Lukas, J., Nacheva, E., Bartkova, J., Stranks, G., De Schouwer, P.J., Lens, D., Bartek, J., Dyer, M.J., Kruger, A.R. & Catovsky, D. (1997) Potential role for concurrent abnormalities of the cyclin D1, 16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia, 11, 64-72.
24. Kremer, M., Dirnhofer, S., Nickl, A., Hoefler, H., Quintanilla-Martinez, L. & Fend, F. (2001) p27 (Kip 1) immunostaining for the differential diagnosis of small B-cell neoplasms in trephine bone marrow biopsies. Modern Pathology, 14, 1022-1029.
25. Leonard, J.P., Schattner, E.J. & Coleman, M. (2001) Biology and management of mantle cell lymphoma. Current Opinion in Oncology, 13, 342-347.
26. Marshansky, V., Wang, X., Bertrand, R., Luo, H., Duguid, W., Chinnadurai, G., Kanaan, N., Vu, M.D. & Wu, J. (2001) Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. Journal of Immunology, 166, 3130-3142.
27. Masdehors, P., Omura, S., Merle-Beral, H., Mentz, F., Cosset, J.-M., Dumont, J., Magdelenat, H. & Delic, J. (1999) Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. British Journal of Haematology, 105, 752-757.
28. Masdehors, P., Merle-Beral, H., Maloum, K., Omura, S., Magdelenat, H. & Delic, J. (2000) Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood, 96, 269-274.
29. O'Connor, O.A., Moskowitz, C.H., Wright, J.J., MacGregor-Cortelli, B., Straus, D., Furst, D., Horse-Grant, D., Schenkein, D.P. & Zelenetz, A.D. (2002) Phase II clinical experience with the proteasome inhibitor PS-341 in patients with indolent lymphomas. Blood, 101, 3063.
30. Orlowski, R.Z., Eswara, J.R., Lafond-Walker, A., Crever, M.R., Orlowski, M. & Dang, C.V. (1998) Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Research, 58, 4342-4348.
31. Orlowski, R.Z., Stinchcombe, T.E., Mitchell, B.S., Shea, T.C., Baldwin, A.S., Stahl, S., Adams, J., Esseltine, D.L., Elliott, P.J., Pien, C.S., Cuerciolini, R., Anderson, J.K., Depcik-Smith, N.D., Bhagat, R., Lehman, M.J., Novick, S.C., O'Connor, O.A. & Soignet, S.L. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Journal of Clinical Oncology, 20, 4420-4427.
32. Ott, M., Bartkova, J., Bartek, J., Dürr, A., Fischer, L., Ott, G., Müller-Hermelink, H.K. & Kreipe, H. (1997) Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. Blood, 90, 3154-3159.
33. Pagano, M., Tam, S.W., Theodoras, A.M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P.R., Draetta, G.F. & Rolfe, M. (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science, 269, 682-685.
34. Pinyol, M., Hernandez, L., Cazorla, M., Balbin, M., Jares, P., Fernandez, P.L., Montserrat, E., Cardesa, A., Lopez-Otin, C. & Campo, E. (1997) Deletions and loss of expression of p16 and p21 genes are associated with aggressive variants of mantle cell lymphoma, Blood, 89, 272-280.
35. Quintanilla-Martinez, L., Thieblemont, C., Fend, F., Kumar, S., Pinyol, M., Campo, E., Jaffe, E.S. & Raffeld, M. (1998) Mantle cell lymphomas lack expression of p27kip1, a cyclin-dependent kinase inhibitor. American Journal of Pathology, 153, 175-182.
36. Quintanilla-Martinez, L., Davies-Hill, T., Fend, F., Calzada-Wack, J., Sorbara, L., Campo, E., Jaffe, E.S. & Raffeld, M. (2002) Sequestration of p27kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphomas (MCL): implications for pathogenesis. Blood, 101, 3181-3187.
37. Richardson, P.G., Berenson, J., Irwin, D., Jagannath, S., Traynor, A., Rajkumar, V., Alsina, M., Kuter, D., Srkalovic, C., Siegel, D., Barlogie, B., Alexanian, R., Orlowski, R., Esseltine, D., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2001) Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Blood, 100, 3223.
38. Saltman, D.L., Cachia, P.C., Dewar, A.E., Ross, F.M., Krajewski, A.S., Ludlam, C. & Steel, C.M. (1988) Characterization of a new non-Hodgkin's lymphoma cell line (NCEB-1) with a chromosomal (11:14) translocation t(11:14) (q13:q32). Blood, 72. 2026-2030.
39. Sherr, C.J. (1996) Cancer cell cycles, Science, 274, 1672-1677.
40. Voges, D., Zwick, P. & Baumeister, W. (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Annual Reviews in Biochemistry, 68, 1015-1068.
41. Wagner, E.F., Hleb, M., Hanna, N. & Sharma, S. (1998) A pivotal role of cyclin D3 and cyclin-dependent kinase inhibitor p27 in the regulation of IL-2, IL-4- or IL-10-mediated human B cell proliferation. Journal of Immunology, 161, 1123-1131.
42. Yatabe, Y., Suzuki, R., Tobinai, K., Matsuno, Y., Ichinohasama, R., Okamoto, R., Yamaguchi, M., Tamaru, J., Uike, N., Hashimoto, Y., Morishima, Y., Suchi, T., Seto, M. & Nakamura, S. (2000) Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood, 95, 2253-2261.
43. Yew, P.R. (2001) Ubiquitin-mediated proteolysis of vertebrate G1-and S-phase regulators. Journal of Cellular Physiology, 187, 1-10.
44. Zukerberg, L.R., Benedict, W.F., Arnold, A., Dyson, N., Harlow, E. & Harris, N.L. (1996) Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1. Blood, 88, 268-276.